NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

市場調查報告書

腎硬變症候群(NS)- 流行病學預測 2028年

Nephrotic Syndrome (NS) Etiologies - Epidemiology Forecast to 2028

出版商 DelveInsight Business Research LLP 商品編碼 911519
出版日期 按訂單生產 內容資訊 英文 80 Pages
商品交期: 2-10個工作天內
價格
腎硬變症候群(NS)- 流行病學預測 2028年 Nephrotic Syndrome (NS) Etiologies - Epidemiology Forecast to 2028
出版日期: 按訂單生產內容資訊: 英文 80 Pages
簡介

美國的腎硬變症候群(NS)的2014年的患病數估計為42萬5,532人。

本報告提供美國的腎硬變症候群(NS)市場調查,疾病概要,各種類的患病數及罹患數的變化與預測,治療方法,指南相關資訊彙整。

目錄

第1章 腎硬變症候群:疾病的背景和概要

  • 簡介
  • 原因
  • 症狀
    • 急性腎硬變症候群的症狀
    • 慢性腎硬變症候群的症狀
    • 腎硬變症候群的併發症
  • 診斷
    • 目標
    • 診斷次序
    • 診斷演算法
  • 分類
  • 病理生理學
    • 急性腎功能衰竭的病理生理學
    • 水腫形成的病理生理學
    • 微小變化腎硬變症候群及侷限性腎小球硬化症的病理生理學
  • 腎硬變症候群的病因

第2章 流行病學和患者人口 - 美國

  • 關鍵意見領袖的意見
  • 主要調查結果
  • 腎硬變症候群(NS)的流行病學趨勢
  • 假設和根據
  • 腎硬變症候群(NS)的總罹患數
  • 腎硬變症候群(NS)的總患病數

第3章 美國的腎硬變症候群(NS)的流行病學

  • 腎硬變症候群(NS)的罹患數
    • 原發性、續發性腎硬變症候群(NS)
    • 原發性、特發性腎硬變症候群(NS)
    • 原發性腎小球腎臟病
    • 續發性腎小球腎臟病
    • 侷限性腎小球硬化症(FSGS)
    • 薄膜性腎臟病(MGN)
    • 特發性薄膜性腎臟病(IMN)
    • 微小變化腎臟病(MCD)
    • IgA腎臟病
    • 薄膜增生性腎絲球腎炎
    • 線維性腎絲球腎炎
    • 其他
  • 腎硬變症候群(NS)的患病數
    • 原發性、續發性腎硬變症候群(NS)
    • 原發性、特發性腎硬變症候群(NS)
    • 原發性腎小球腎臟病
    • 續發性腎小球腎臟病
    • 侷限性腎小球硬化症(FSGS)
    • 薄膜性腎臟病(MGN)
    • 特發性薄膜性腎臟病(IMN)
    • 微小變化腎臟病(MCD)
    • IgA腎臟病
    • 薄膜增生性腎絲球腎炎
    • 線維性腎絲球腎炎

第4章 治療

  • 腎硬變症候群(NS)的常用醫藥品
  • 一般的治療方法
  • 腎硬變症候群的治療指南

第5章 腎硬變症候群的KDIGO指南

第6章 附錄

  • 調查手法

第7章 DelveInsight的服務內容

第8章 免責聲明

第9章 關於DelveInsight

目錄
Product Code: DIEI0383

DelveInsight's 'Nephrotic Syndrome (NS) Etiologies - Epidemiology Forecast to 2028' report delivers an in-depth understanding of the disease, historical & forecasted epidemiology of Nephrotic Syndrome (NS) across all etiologies in the United States for period of 2014-2028.

Geography Covered

  • The United States

Study Period: 2014-2028

Nephrotic Syndrome (NS) - Disease Understanding

Nephrotic syndrome (NS) is a clinical syndrome defined by massive proteinuria (greater than 40 mg/m2 per hour) responsible for hypoalbuminemia (less than 30 g/L), with resulting hyperlipidemia, edema, and various complications. It is caused by increased permeability through the damaged basement membrane in the renal glomerulus especially infectious or thromboembolic.

Nephrotic Syndrome Epidemiology

The Nephrotic Syndrome epidemiology division provide the insights about historical and current patient pool and forecasted trend in The United States across various etiologies. The epidemiology data for Nephrotic Syndrome are categorized through all possible etiology to give a better understanding about the Disease scenario in the United States. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.

Nephrotic Syndrome Epidemiology Segmentation

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (total Incident population, total prevalent cases) scenario of Nephrotic Syndrome across etiologies such as Primary Glomerulonephropathies, Secondary Glomerulonephropathies, Focal Segmental Glomerulosclerosis (FSGS), Membranous nephropathy (MGN),and others in the United States from 2014-2028.

The DelveInsight report also provides the epidemiology trends observed in the United States during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.

According to DelveInsight, the total number of prevalent cases of Nephrotic Syndrome in United States was found to be 425,532 in the year 2014.

Report Scope

  • The report covers detailed overview of Nephrotic Syndrome explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
  • The report provides the insight about the historical and forecasted patient pool of Nephrotic Syndrome in the United States
  • The Report assesses the risk and burden of the disease
  • The Report helps to recognize the growth opportunities in the United States with respect to the patient population
  • The report provides the segmentation of the disease epidemiology by prevalence and incidence of Nephrotic Syndrome across all etiologies in the United States.

Key strengths

  • 10 Year Forecast of Nephrotic Syndrome epidemiology
  • United States
  • Total Prevalent Cases of Nephrotic Syndrome
  • Total Incident Cases of Nephrotic Syndrome
  • Prevalent and Incident Cases according to Etiologies: Primary Glomerulonephropathies, Secondary Glomerulonephropathies, Focal Segmental Glomerulosclerosis (FSGS), Membranous nephropathy (MGN), Idiopathic membranous nephropathy (IMN), Minimal-change nephropathy (MCD), IgA Nephropathy, Membrano-proliferative glomerulonephritis (MPGN), Fibrillary Glomerulonephritis (FGN), Immunotactoid Glomerulopathy (ITG), and others.

Key assessments

  • Patient Segmentation
  • Disease Risk & Burden
  • Risk of disease by the segmentation

Table of Contents

1. Nephrotic Syndrome: Disease Background and Overview

  • 1.1. Introduction
  • 1.2. Causes
  • 1.3. Symptoms
    • 1.3.1. Symptoms of Acute Nephrotic Syndrome
    • 1.3.2. Symptoms of Chronic Nephrotic Syndrome
    • 1.3.3. Complications of Nephrotic Syndrome
  • 1.4. Diagnosis
    • 1.4.1. Goals
    • 1.4.2. Diagnostic Procedures
      • 1.4.2.1. Other diagnostic procedures for NS associated conditions
    • 1.4.3. Diagnostic Algorithm
  • 1.5. Classification
  • 1.6. Pathophysiology
    • 1.6.1. Pathophysiology of acute renal failure in the Nephrotic Syndrome
    • 1.6.2. Pathophysiology of Edema Formation in the Nephrotic Syndrome
    • 1.6.3. Pathophysiology of Minimal Change Nephrotic Syndrome and Focal Segmental Glomerulosclerosis
  • 1.7. Etiology of Nephrotic Syndrome
    • 1.7.1. Primary causes
    • 1.7.2. Secondary causes

2. Epidemiology and Patient Population - The United States

  • 2.1. KOL Views
  • 2.2. Key Findings
  • 2.3. Nephrotic Syndrome Epidemiology Trends
  • 2.4. Assumptions and Rationale
  • 2.5. Incidence of Nephrotic Syndrome across all etiologies
  • 2.6. Prevalence of Nephrotic Syndrome across all etiologies

3. Epidemiology of Nephrotic Syndrome in the United States

  • 3.1. Incident Cases of Nephrotic Syndrome
    • 3.1.1. Incident Cases of Nephrotic Syndrome by primary and secondary etiologies
    • 3.1.2. Incident Cases of Primary Idiopathic Nephrotic Syndrome across all etiologies
    • 3.1.3. Incident Cases of Primary Glomerulonephropathies
    • 3.1.4. Incident Cases of Secondary Glomerulonephropathies
    • 3.1.5. Incident Cases of Focal Segmental Glomerulosclerosis (FSGS)
    • 3.1.6. Incident Cases of Membranous nephropathy (MGN)
    • 3.1.7. Incident Cases of Idiopathic membranous nephropathy (IMN)
    • 3.1.8. Incident Cases of Minimal-¬change nephropathy (MCD)
    • 3.1.9. Incident Cases of IgA Nephropathy
    • 3.1.10. Incident Cases of Membrano-proliferative glomerulonephritis (MPGN)
    • 3.1.11. Incident Cases of Fibrillary Glomerulonephritis (FGN)
      • 3.1.11.1. Incident Cases of Immunotactoid Glomerulopathy (ITG)
    • 3.1.12. Incident Cases of other etiologies
  • 3.2. Prevalent Cases of Nephrotic Syndrome
    • 3.2.1. Prevalent Cases of Nephrotic Syndrome by primary and secondary etiologies
    • 3.2.2. Prevalent Cases of Nephrotic Syndrome across all etiologies
    • 3.2.3. Prevalent Cases of Primary Glomerulonephropathies
    • 3.2.4. Prevalent Cases of Secondary Glomerulonephropathies
    • 3.2.5. Prevalent Cases of Focal Segmental Glomerulosclerosis (FSGS)
    • 3.2.6. Prevalent Cases of Membranous nephropathy (MGN)
    • 3.2.7. Prevalent Cases of Idiopathic membranous nephropathy (IMN)
    • 3.2.8. Prevalent Cases of Minimal-¬change nephropathy (MCD)
    • 3.2.9. Prevalent Cases of IgA Nephropathy
    • 3.2.10. Prevalent Cases of Membrano-proliferative glomerulonephritis (MPGN)
    • 3.2.11. Prevalent Cases of Fibrillary Glomerulonephritis (FGN)
    • 3.2.12. Prevalent Cases of Immunotactoid Glomerulopathy (ITG)
    • 3.2.13. Prevalent Cases of other etiologies

4. Treatment

  • 4.1. Routinely Prescribed Therapeutics for NS
  • 4.2. General Treatment Measures
  • 4.3. Treatment Guidelines for Nephrotic Syndrome

5. KDIGO Guidelines for Nephrotic Syndrome

6. Appendix

  • 6.1. Report Methodology

7. DelveInsight Capabilities

8. Disclaimer

9. About DelveInsight

List of Tables

  • Table 1: Secondary causes of nephrotic syndrome
  • Table 2: Complications of Nephrotic Syndrome
  • Table 3: Incident Cases of Nephrotic Syndrome (2014-2028)
  • Table 4: Incident Cases of Nephrotic Syndrome by primary and secondary etiologies (2014-2028)
  • Table 5: Incident Cases of Nephrotic Syndrome across all etiologies (2014-2028)
  • Table 6: Incident Cases of Primary Glomerulonephropathies (2014-2028)
  • Table 7: Incident Cases of Secondary Glomerulonephropathies (2014-2028)
  • Table 8: Incident Cases of Focal Segmental Glomerulosclerosis (2014-2028)
  • Table 9: Incident Cases of Membranous nephropathy (2014-2028)
  • Table 10: Incident Cases of Idiopathic membranous nephropathy (2014-2028)
  • Table 11: Incident Cases of Minimal-¬change nephropathy (2014-2028)
  • Table 12: Incident Cases of IgA Nephropathy (2014-2028)
  • Table 13: Incident Cases of Membrano-proliferative glomerulonephritis (2014-2028)
  • Table 14: Incident Cases of Fibrillary Glomerulonephritis (2014-2028)
  • Table 15: Incident Cases of Immunotactoid Glomerulopathy (2014-2028)
  • Table 16: Incident Cases of other etiologies (2014-2028)
  • Table 17: Prevalent Cases of Nephrotic Syndrome (2014-2028)
  • Table 18: Prevalent Cases of Nephrotic Syndrome by primary and secondary etiologies (2014-2028)
  • Table 19: Prevalent Cases of Nephrotic Syndrome across all etiologies (2014-2028)
  • Table 20: Prevalent Cases of Primary Glomerulonephropathies (2014-2028)
  • Table 21: Prevalent Cases of Secondary Glomerulonephropathies (2014-2028)
  • Table 22: Prevalent Cases of Focal Segmental Glomerulosclerosis (2014-2028)
  • Table 23: Prevalent Cases of Membranous nephropathy (2014-2028)
  • Table 24: Prevalent Cases of Idiopathic membranous nephropathy (2014-2028)
  • Table 25: Prevalent Cases of Minimal-¬change nephropathy (2014-2028)
  • Table 26: Prevalent Cases of IgA Nephropathy (2014-2028)
  • Table 27: Prevalent Cases of Membrano-proliferative glomerulonephritis (2014-2028)
  • Table 28: Prevalent Cases of Fibrillary Glomerulonephritis (2014-2028)
  • Table 29: Prevalent Cases of Immunotactoid Glomerulopathy (2014-2028)
  • Table 30: Prevalent Cases of other etiologies (2014-2028)

List of Figures

  • Figure 1: Daily albumin turnover in normal individuals and patients with nephrotic syndrome
  • Figure 2: Diagnosis of Nephrotic Syndrome in Adults
  • Figure 3: Classification of Nephrotic Syndrome
  • Figure 4: Pathophysiology of Nephrotic Syndrome.
  • Figure 5: Mechanisms of sodium retention in nephrotic syndrome.
  • Figure 6: Schematic diagram of the pathogenesis of minimal change nephrotic syndrome (MCNS)
  • Figure 7: Schematic diagram of the pathogenesis of focal segmental glomerulosclerosis
  • Figure 8: Incident Cases of Nephrotic Syndrome (2014-2028)
  • Figure 9: Incident Cases of Nephrotic Syndrome by primary and secondary etiologies (2014-2028)
  • Figure 10: Incident Cases of Primary Idiopathic Nephrotic Syndrome across all etiologies (2014-2028)
  • Figure 11: Incident Cases of Primary Glomerulonephropathies (2014-2028)
  • Figure 12: Incident Cases of Secondary Glomerulonephropathies (2014-2028)
  • Figure 13: Incident Cases of Focal Segmental Glomerulosclerosis (2014-2028)
  • Figure 14: Incident Cases of Membranous nephropathy (2014-2028)
  • Figure 15: Incident Cases of Idiopathic membranous nephropathy (2014-2028)
  • Figure 16: Incident Cases of Minimal-¬change nephropathy (2014-2028)
  • Figure 17: Incident Cases of IgA Nephropathy (2014-2028)
  • Figure 18: Incident Cases of Membrano-proliferative glomerulonephritis (2014-2028)
  • Figure 19: Incident Cases of Fibrillary Glomerulonephritis (2014-2028)
  • Figure 20: Incident Cases of Immunotactoid Glomerulopathy (2014-2028)
  • Figure 21: Incident Cases of other etiologies (2014-2028)
  • Figure 22: Prevalent Cases of Nephrotic Syndrome (2014-2028)
  • Figure 23: Prevalent Cases of Nephrotic Syndrome by primary and secondary etiologies (2014-2028)
  • Figure 24: Prevalent Cases of Nephrotic Syndrome across all etiologies (2014-2028)
  • Figure 25: Prevalent Cases of Primary Glomerulonephropathies (2014-2028)
  • Figure 26: Prevalent Cases of Secondary Glomerulonephropathies (2014-2028)
  • Figure 27: Prevalent Cases of Focal Segmental Glomerulosclerosis (2014-2028)
  • Figure 28: Prevalent Cases of Membranous nephropathy (2014-2028)
  • Figure 29: Prevalent Cases of Idiopathic membranous nephropathy (2014-2028)
  • Figure 30: Prevalent Cases of Minimal-¬change nephropathy (2014-2028)
  • Figure 31: Prevalent Cases of IgA Nephropathy (2014-2028)
  • Figure 32: Prevalent Cases of Membrano-proliferative glomerulonephritis (2014-2028)
  • Figure 33: Prevalent Cases of Fibrillary Glomerulonephritis (2014-2028)
  • Figure 34: Prevalent Cases of Immunotactoid Glomerulopathy (2014-2028)
  • Figure 35: Prevalent Cases of other etiologies (2014-2028)
  • Figure 36: Routinely Prescribed Therapeutics for NS